The molecular basis of the neutralization breadth of the RBD-specific antibody CoV11.

SARS-CoV-2 VH 3-53 germline gene (IGHV3-53*01) neutralizing antibody receptor binding domain (RBD) variants of concern (VOC)

Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2023
Historique:
received: 02 03 2023
accepted: 16 05 2023
medline: 20 6 2023
pubmed: 19 6 2023
entrez: 19 6 2023
Statut: epublish

Résumé

SARS-CoV-2, the virus behind the COVID-19 pandemic, has changed over time to the extent that the current virus is substantially different from what originally led to the pandemic in 2019-2020. Viral variants have modified the severity and transmissibility of the disease and continue do so. How much of this change is due to viral fitness versus a response to immune pressure is hard to define. One class of antibodies that continues to afford some level of protection from emerging variants are those that closely overlap the binding site for angiotensin-converting enzyme 2 (ACE2) on the receptor binding domain (RBD). Some members of this class that were identified early in the course of the pandemic arose from the V

Identifiants

pubmed: 37334379
doi: 10.3389/fimmu.2023.1178355
pmc: PMC10272436
doi:

Substances chimiques

Antibodies 0
Blood Group Antigens 0

Types de publication

Journal Article Research Support, N.I.H., Intramural Research Support, U.S. Gov't, Non-P.H.S. Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1178355

Subventions

Organisme : BLRD VA
ID : I01 BX005469
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI147870
Pays : United States

Informations de copyright

Copyright © 2023 Tolbert, Chen, Sun, Benlarbi, Ding, Manickam, Pangaro, Nguyen, Gottumukkala, Côté, Gonzalez, Finzi, Tehrani, Sajadi and Pazgier.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Immunity. 2021 Aug 10;54(8):1853-1868.e7
pubmed: 34331873
Cell. 2020 Jul 9;182(1):73-84.e16
pubmed: 32425270
Nature. 2022 Feb;602(7896):294-299
pubmed: 34818667
Emerg Microbes Infect. 2021 Dec;10(1):1097-1111
pubmed: 33944697
Methods Enzymol. 1997;276:307-26
pubmed: 27754618
Science. 2020 Aug 21;369(6506):956-963
pubmed: 32540903
Nat Rev Microbiol. 2021 Mar;19(3):141-154
pubmed: 33024307
Methods Enzymol. 1997;277:366-96
pubmed: 18488318
Proc Natl Acad Sci U S A. 2023 Jun 6;120(23):e2220948120
pubmed: 37253011
Nature. 2020 Dec;588(7839):682-687
pubmed: 33045718
Science. 2020 Aug 7;369(6504):643-650
pubmed: 32540902
Nature. 2021 Dec;600(7888):204-207
pubmed: 34876665
Cell. 2021 May 27;184(11):2939-2954.e9
pubmed: 33852911
Nat Commun. 2021 Jul 9;12(1):4210
pubmed: 34244522
Methods Protoc. 2018 Jan 22;1(1):
pubmed: 31164554
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
Science. 2020 Aug 28;369(6507):1119-1123
pubmed: 32661058
Acta Crystallogr D Biol Crystallogr. 1994 Sep 1;50(Pt 5):760-3
pubmed: 15299374
Science. 2012 May 25;336(6084):1030-3
pubmed: 22628654
Nat Commun. 2020 Nov 26;11(1):6013
pubmed: 33243994
Cell Rep. 2023 Jan 31;42(1):111998
pubmed: 36656710
iScience. 2023 Jan 20;26(1):105783
pubmed: 36514310
Proc Natl Acad Sci U S A. 2021 Mar 2;118(9):
pubmed: 33579792
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
Nat Commun. 2020 Oct 27;11(1):5413
pubmed: 33110068
Cell Rep. 2022 Jan 11;38(2):110210
pubmed: 34971573
Nature. 2020 May;581(7807):221-224
pubmed: 32225175
Acta Biomed. 2022 Mar 14;93(1):e2022179
pubmed: 35315394
Proc Natl Acad Sci U S A. 2020 May 26;117(21):11727-11734
pubmed: 32376634
Science. 2021 Oct 22;374(6566):472-478
pubmed: 34554826
Cell Rep. 2020 Oct 20;33(3):108274
pubmed: 33027617
Cell. 2021 Apr 15;184(8):2201-2211.e7
pubmed: 33743891
New Microbes New Infect. 2021 Sep;43:100929
pubmed: 34336227
Cell. 2021 Jun 10;184(12):3205-3221.e24
pubmed: 34015271
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):213-21
pubmed: 20124702
Cell Res. 2021 May;31(5):517-525
pubmed: 33731853
Ann Immunol (Paris). 1976 Jun-Jul;127(3-4):239-52
pubmed: 822774
Nature. 2020 May;581(7807):215-220
pubmed: 32225176
Vaccines (Basel). 2023 Jan 21;11(2):
pubmed: 36851122

Auteurs

William D Tolbert (WD)

Infectious Disease Division, Department of Medicine of Uniformed Services University of the Health Sciences, Bethesda, MD, United States.

Yaozong Chen (Y)

Infectious Disease Division, Department of Medicine of Uniformed Services University of the Health Sciences, Bethesda, MD, United States.

Lulu Sun (L)

Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD, United States.

Mehdi Benlarbi (M)

Centre de recherche du Centre hospitalier de l'Université de Montréal (CHUM), Montreal, QC, Canada.
Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC, Canada.

Shilei Ding (S)

Centre de recherche du Centre hospitalier de l'Université de Montréal (CHUM), Montreal, QC, Canada.

Rohini Manickam (R)

Infectious Disease Division, Department of Medicine of Uniformed Services University of the Health Sciences, Bethesda, MD, United States.

Emily Pangaro (E)

Infectious Disease Division, Department of Medicine of Uniformed Services University of the Health Sciences, Bethesda, MD, United States.

Dung N Nguyen (DN)

Infectious Disease Division, Department of Medicine of Uniformed Services University of the Health Sciences, Bethesda, MD, United States.

Suneetha Gottumukkala (S)

Infectious Disease Division, Department of Medicine of Uniformed Services University of the Health Sciences, Bethesda, MD, United States.

Marceline Côté (M)

Department of Biochemistry, Microbiology and Immunology, and Centre for Infection, Immunity, and Inflammation, University of Ottawa, Ottawa, ON, Canada.

Frank J Gonzalez (FJ)

Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD, United States.

Andrés Finzi (A)

Centre de recherche du Centre hospitalier de l'Université de Montréal (CHUM), Montreal, QC, Canada.
Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC, Canada.

Zahra R Tehrani (ZR)

Division of Vaccine Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, United States.
Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, United States.

Mohammad M Sajadi (MM)

Division of Vaccine Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, United States.
Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, United States.
Department of Medicine, Baltimore Veterans Health Administration (VA) Medical Center, Baltimore, MD, United States.

Marzena Pazgier (M)

Infectious Disease Division, Department of Medicine of Uniformed Services University of the Health Sciences, Bethesda, MD, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH